Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial

Torben Plesner*, Meletios A. Dimopoulos, Albert Oriol, Jesus San-Miguel, Nizar J. Bahlis, Neil Rabin, Kenshi Suzuki, Sung Soo Yoon, Dina Ben-Yehuda, Gordon Cook, Hartmut Goldschmidt, Sebastian Grosicki, Xiang Qin, John Fastenau, Wendy Garvin, Robin Carson, Thomas Renaud, Katharine S. Gries

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

In the phase 3 POLLUX trial, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly improved progression-free survival in patients with relapsed/refractory multiple myeloma (RRMM) compared with lenalidomide and dexamethasone (Rd) alone. Here, we present patient-reported outcomes (PROs) from POLLUX, assessed using the validated European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item (EORTC QLQ-C30) and the EuroQol 5-dimensional descriptive system (EQ-5D-5L) questionnaires. Changes from baseline are presented as least-squares mean changes with 95% confidence intervals (CIs) derived from a mixed-effects model. PRO assessment compliance rates were high and similar in both D-Rd and Rd groups through cycle 40 (week 156). In this on-treatment analysis, mean changes from baseline were significantly greater in EORTC QLQ-C30 global health status, physical functioning, and pain scores in the D-Rd group versus the Rd group at multiple time points; however, magnitude of changes was low, suggesting no meaningful impact on health-related quality of life (HRQoL). Subgroup results were similar to those in the overall population. In the POLLUX study, baseline HRQoL was maintained with prolonged D-Rd treatment. These findings complement the sustained and significant improvement in progression-free survival observed with D-Rd and supports its use in patients with RRMM. Clinical trial registration: NCT02076009.

Original languageEnglish
JournalBritish Journal of Haematology
Volume194
Issue number1
Pages (from-to)132-139
ISSN0007-1048
DOIs
Publication statusPublished - Jul 2021

Bibliographical note

Publisher Copyright:
© 2021 British Society for Haematology and John Wiley & Sons Ltd

Keywords

  • daratumumab
  • health-related quality of life
  • patient-reported outcomes
  • POLLUX
  • relapsed/refractory multiple myeloma

Fingerprint

Dive into the research topics of 'Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial'. Together they form a unique fingerprint.

Cite this